About the Company
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on DBV Technologies S.A.
DBV Technologies Adjusts ADS Ratio to Meet Nasdaq Rules
An update from DBV Technologies SA – American ( (DBVT) ) is now available.DBV Technologies has announced a significant change in the ratio of its American Depositary Shares (ADSs) to its ...
DBV Technologies Reports Positive Phase 3 Study Results
More about DBV Technologies SA – American DBV Technologies SA is a clinical-stage biopharmaceutical company that focuses on developing treatments for food allergies.
DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ETCompany ParticipantsKatie Matthews - Head of Investor ...
DBV Technologies Receives Buy Rating: Efficacy and Safety of Viaskin ...
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin ...
DBV Technologies S.A.: DBV Technologies announces filing of 2025 Half ...
DBV TECHNOLOGIES SA WKN: A1JWB7|ISIN: FR0010417345|Ticker-Symbol: DBV Frankfurt 15.08.25 | 08:05 1,642Euro 0,00 % 0,000 Branche Biotechnologie Aktienmarkt Sonstige 1-Jahres-Chart 5-Tage-Chart ...
DBV Technologies S.A.: DBV Technologies Announces Appointment of James ...
Châtillon, France, July 22, 2025 DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Market: DBVT) ...
Here’s What Hedge Funds Think About DBV Technologies SA – ADR (DBVT)
Among these funds, Baker Bros. Advisors held the most valuable stake in DBV Technologies SA - ADR (NASDAQ:DBVT), which was worth $45.3 million at the end of the second quarter.
Why DBV Technologies S.A. (DBVT) is Surging in 2025
DBV Technologies S.A. (NASDAQ:DBVT) stock is up 176.05% year-to-date. Overall, DBVT ranks 6th on our list of healthcare stocks that are surging in 2025.
DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2020 Results ...
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2020 Earnings Conference Call March 11, 2021 5:00 PM ETCompany ParticipantsAnne Pollak - Head of Investor ...
DBV Technologies Provides Update On Viaskin Peanut BLA For Children ...
* DBV TECHNOLOGIES SA - ALLERGENIC PRODUCTS ADVISORY COMMITTEE MEETING TO DISCUSS BLA WILL NO LONGER TAKE PLACE AS PREVIOUSLY SCHEDULED ON MAY 15, 2020 Source text for Eikon: Further company coverage: ...
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript
DBV Technologies S.A. misses on earnings expectations. Reported EPS is $-0.1742 EPS, expectations were $-0.15. Operator: Welcome to the DBV’s Third Quarter Financial Results and Business and ...
Similar Companies
Loading the latest forecasts...